We are delighted to announce that we have opened a new facility at Mayday University Hospital to complement our units and offices in St George’s Hospital and St George’s University of London. This ground breaking move means Richmond Pharmacology is the UK’s first CRO with a dedicated Phase I and clinical trials unit to be based in 2 acute NHS Teaching Hospitals.
We were recently featured in the Japanese publication Japan Medicine, which reported on our business trip to Japan in December. Dr Jörg Täubel, CEO of Richmond Pharmacology, made the trip to develop relationships with key business partners.
Richmond Pharmacology's new dedicated Japanese recruitment team have successfully delivered 2 Japanese panels for Bridging Studies in November and December this year. We are already ahead of target for our Japanese/Caucasian Bridging Studies requirements in 2005.
The research and development new treatments and cures open the possibility of enhancing the standard of living for millions of people worldwide. Volunteer involvement is a crucial part of this, but before participation is allowed each volunteer must provide the researchers with their signed consent. Why is informed consent so important?
Richmond Pharmacology has recently rolled out a high profile advertising campaign to Japanese people in the UK and Germany. Find out why in this article originally published in Journey magazine.
We recently featured the article ‘Chance for a Cure’ describing the pivotal role clinical trials play in the development of crucial new medicines. As a result of the level of interest expressed in the safety aspect of clinical trials Dr. Jörg Täubel of Richmond Pharmacology explained the extensive safety measures that are taken before every clinical trial commences.
The medical world continues to develop new treatments that are saving lives and cure diseases every day in every country. But have you ever stopped to consider the years of research that go into giving a sick person a chance for a cure?